Early tumour response assessment may avoid serious immune‐related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma. (1st March 2022)

Record Type:: Journal Article
Title:: Early tumour response assessment may avoid serious immune‐related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma. (1st March 2022)
Main Title:: Early tumour response assessment may avoid serious immune‐related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma
Authors:: Maeda, T.
Hiura, A.
Uehara, J.
Toyoshima, R.
Nakagawa, T.
Yoshino, K.
Abstract:
Is Part Of:: British journal of dermatology. Volume 186:Number 3(2022)
Journal:: British journal of dermatology
Issue:: Volume 186:Number 3(2022)
Issue Display:: Volume 186, Issue 3 (2022)
Year:: 2022
Volume:: 186
Issue:: 3
Issue Sort Value:: 2022-0186-0003-0000
Page Start:: 587
Page End:: 588
Publication Date:: 2022-03-01
Subjects:: Dermatology -- Periodicals
Skin -- Diseases -- Periodicals
616.5
Journal URLs:: http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2133 ↗
https://academic.oup.com/bjd ↗
http://onlinelibrary.wiley.com/ ↗
DOI:: 10.1111/bjd.20879 ↗
Languages:: English
ISSNs:: 0007-0963
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 2307.400000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 24768.xml